Literature DB >> 31316003

Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".

Danilo Perrotti1,2, Anupriya Agarwal3, Claire M Lucas4, Goutham Narla5, Paolo Neviani6, Maria D Odero7, Peter P Ruvolo8, Nicole M Verrills9.   

Abstract

LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31316003      PMCID： PMC7402218          DOI： 10.1126/scitranslmed.aau0416

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  6 in total

1.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Authors:  Paolo Neviani; Jason G Harb; Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Justin J Ellis; Gregory Ferenchak; Adrienne M Dorrance; Carolyn A Paisie; Anna M Eiring; Yihui Ma; Hsiaoyin C Mao; Bin Zhang; Mark Wunderlich; Philippa C May; Chaode Sun; Sahar A Saddoughi; Jacek Bielawski; William Blum; Rebecca B Klisovic; Janelle A Solt; John C Byrd; Stefano Volinia; Jorge Cortes; Claudia S Huettner; Steffen Koschmieder; Tessa L Holyoake; Steven Devine; Michael A Caligiuri; Carlo M Croce; Ramiro Garzon; Besim Ogretmen; Ralph B Arlinghaus; Ching-Shih Chen; Robert Bittman; Peter Hokland; Denis-Claude Roy; Dragana Milojkovic; Jane Apperley; John M Goldman; Alistair Reid; James C Mulloy; Ravi Bhatia; Guido Marcucci; Danilo Perrotti
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia.

Authors:  Damian Lai; Min Chen; Jiechuang Su; Xiaohu Liu; Katharina Rothe; Kaiji Hu; Donna L Forrest; Connie J Eaves; Gregg B Morin; Xiaoyan Jiang
Journal:  Sci Transl Med       Date:  2018-02-07       Impact factor: 17.956

3.  Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Authors:  Vincent Chung; Aaron S Mansfield; Fadi Braiteh; Donald Richards; Henry Durivage; Richard S Ungerleider; Francis Johnson; John S Kovach
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

4.  B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies.

Authors:  Gang Xiao; Lai N Chan; Lars Klemm; Daniel Braas; Zhengshan Chen; Huimin Geng; Qiuyi Chen Zhang; Ali Aghajanirefah; Kadriye Nehir Cosgun; Teresa Sadras; Jaewoong Lee; Tamara Mirzapoiazova; Ravi Salgia; Thomas Ernst; Andreas Hochhaus; Hassan Jumaa; Xiaoyan Jiang; David M Weinstock; Thomas G Graeber; Markus Müschen
Journal:  Cell       Date:  2018-03-15       Impact factor: 41.582

5.  AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.

Authors:  Liang L Zhou; Yun Zhao; Ashley Ringrose; Donna DeGeer; Erin Kennah; Ann E-J Lin; Guoqing Sheng; Xiao-Jiang Li; Ali Turhan; Xiaoyan Jiang
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

Review 6.  From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.

Authors:  Maria Ciccone; George A Calin; Danilo Perrotti
Journal:  Front Oncol       Date:  2015-02-16       Impact factor: 6.244
  6 in total
  3 in total

1.  Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions.

Authors:  Giovannino Silvestri; Rossana Trotta; Lorenzo Stramucci; Justin J Ellis; Jason G Harb; Paolo Neviani; Shuzhen Wang; Ann-Kathrin Eisfeld; Christopher J Walker; Bin Zhang; Klara Srutova; Carlo Gambacorti-Passerini; Gabriel Pineda; Catriona H M Jamieson; Fabio Stagno; Paolo Vigneri; Georgios Nteliopoulos; Philippa C May; Alistair G Reid; Ramiro Garzon; Denis-Claude Roy; Moutuaata M Moutuou; Martin Guimond; Peter Hokland; Michael W Deininger; Garrett Fitzgerald; Christopher Harman; Francesco Dazzi; Dragana Milojkovic; Jane F Apperley; Guido Marcucci; Jianfei Qi; Katerina Machova Polakova; Ying Zou; Xiaoxuan Fan; Maria R Baer; Bruno Calabretta; Danilo Perrotti
Journal:  Blood Cancer Discov       Date:  2020-07

Review 2.  Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.

Authors:  Govinda Poudel; Molly G Tolland; Timothy P Hughes; Ilaria S Pagani
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

Review 3.  Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia.

Authors:  Christian Boni; Claudio Sorio
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.